ArticleCureus2026
Spectrum of Hemoglobinopathies in Microcytic Hypochromic Anemia: A Cross-Sectional Study From Western India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHemoglobinopathies are common genetic disorders with high prevalence in India. This study aimed to determine the spectrum of hemoglobinopathies among patients with microcytic hypochromic anemia at a tertiary care center in Jaipur, Western India.
methodsThis cross-sectional study enrolled 150 patients with microcytic hypochromic anemia (mean corpuscular volume (MCV) <80 fL, mean corpuscular hemoglobin (MCH) <27 pg) and clinically suspected hemoglobinopathy. Patients with a recent blood transfusion were excluded. Venous blood samples were analyzed using complete blood count and high-performance liquid chromatography (HPLC). Statistical analysis was performed using chi-square tests.
resultsAmong 150 patients, 63 (42.0%) were diagnosed with the beta-thalassemia trait, making it the most common abnormality. A normal HPLC pattern was observed in 50 (33.3%) patients. Beta-thalassemia major was diagnosed in 12 (8.0%) patients, followed by hemoglobin S (HbS) trait in seven (4.7%), hemoglobin E (HbE) homozygous in six (4.0%), hereditary persistence of fetal hemoglobin (HPFH) in four (2.7%), and other rare variants in eight (5.3%) patients. Female predominance was observed among abnormal cases (62.0% females vs. 38.0% males; female: male ratio 1.6:1; χ²=5.76, p=0.016). The highest proportion of cases was observed in the <10 years age group (30.0%), followed by the 21-30 years age group (22.0%) (χ²=28.43, p=0.005).
conclusionBeta-thalassemia trait is the predominant hemoglobinopathy in this region. High prevalence in children under 10 years and females of reproductive age underscores the need for targeted screening programs in schools and antenatal clinics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.